Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
Provided By PR Newswire
Last update: Aug 20, 2025
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025
Topline results anticipated in 2026
Positions Atossa for transition into registrational Phase 3 development
Read more at prnewswire.com
